Drug Interactions between Adempas and gabapentin
This report displays the potential drug interactions for the following 2 drugs:
- Adempas (riociguat)
- gabapentin
Interactions between your drugs
No interactions were found between Adempas and gabapentin. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Adempas
A total of 283 drugs are known to interact with Adempas.
- Adempas is in the drug class vasodilators.
- Adempas is used to treat Pulmonary Arterial Hypertension.
gabapentin
A total of 269 drugs are known to interact with gabapentin.
- Gabapentin is in the drug class gamma-aminobutyric acid analogs.
-
Gabapentin is used to treat the following conditions:
- Alcohol Use Disorder (off-label)
- Alcohol Withdrawal (off-label)
- Anxiety (off-label)
- Back Pain
- Benign Essential Tremor (off-label)
- Bipolar Disorder (off-label)
- Burning Mouth Syndrome (off-label)
- Carpal Tunnel Syndrome (off-label)
- Chronic Kidney Disease-Associated Pruritus (off-label)
- Chronic Pain
- Cluster-Tic Syndrome (off-label)
- Cough (off-label)
- Diabetic Peripheral Neuropathy (off-label)
- Epilepsy
- Erythromelalgia (off-label)
- Fibromyalgia (off-label)
- Hiccups (off-label)
- Hot Flashes (off-label)
- Hyperhidrosis (off-label)
- Insomnia (off-label)
- Lhermitte's Sign (off-label)
- Migraine (off-label)
- Nausea/Vomiting, Chemotherapy Induced (off-label)
- Neuropathic Pain (off-label)
- Occipital Neuralgia (off-label)
- Pain (off-label)
- Periodic Limb Movement Disorder (off-label)
- Peripheral Neuropathy (off-label)
- Postherpetic Neuralgia
- Postmenopausal Symptoms (off-label)
- Primary Orthostatic Tremor (off-label)
- Pruritus (off-label)
- Pudendal Neuralgia (off-label)
- Reflex Sympathetic Dystrophy Syndrome (off-label)
- Restless Legs Syndrome (off-label)
- Seizures
- Small Fiber Neuropathy (off-label)
- Spondylolisthesis (off-label)
- Syringomyelia (off-label)
- Transverse Myelitis (off-label)
- Trigeminal Neuralgia (off-label)
- Vulvodynia (off-label)
Drug and food interactions
gabapentin food
Applies to: gabapentin
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References
- Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc. (1990):
- "Product Information. Fycompa (perampanel)." Eisai Inc (2012):
- "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc (2015):
riociguat food
Applies to: Adempas (riociguat)
ADJUST DOSE: Smoking may decrease the plasma concentrations of riociguat. The proposed mechanism is induction of the CYP450 1A1-mediated metabolism of riociguat by polycyclic aromatic hydrocarbons present in cigarette smoke. CYP450 1A1 is responsible for the formation of the major active metabolite, M1, which has just 1/3 to 1/10 the pharmacologic activity of riociguat. According to the product labeling, plasma concentrations of riociguat are reduced by 50% to 60% in smokers compared to nonsmokers.
MANAGEMENT: Riociguat dosages higher than 2.5 mg three times a day may be considered in cigarette smokers, if tolerated, so as to match the exposure seen in nonsmoking patients. However, safety and effectiveness of higher dosages have not been established. A dosage reduction should be considered in patients who stop smoking during treatment with riociguat.
References
- "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc (2013):
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.